Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F20%3A00538083" target="_blank" >RIV/67985904:_____/20:00538083 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/B978-0-12-820016-2.00015-X" target="_blank" >http://dx.doi.org/10.1016/B978-0-12-820016-2.00015-X</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/B978-0-12-820016-2.00015-X" target="_blank" >10.1016/B978-0-12-820016-2.00015-X</a>

Result language
angličtina
Original language name
Current development in toxicity, clinical trials guidelines for regulatory aspects of breast cancer nanomedicines
Original language description
The existing challenges in breast cancer therapy and treatment has made researchers across the globe to come together and address the issues pertaining to existing therapy. Nanomedicine has emerged as an effective area in treatment of breast cancer therapy. However, toxicity issues of nanomaterial should be taken care of before going on further with clinical trials. In this regard, the countries and agencies have also formed some regulatory guidelines to be followed by scientist and researchers working in this field. The chapter focuses on some common nanomaterials employed for breast cancer therapy, their toxicity issues, possible reasons for causing toxicity, current innovative therapies for cancer treatment, and regulatory aspect of breast cancer nanomedicine.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)